Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  Life Science

• Publication date

  1985-01-21

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1016/0024-3205(85)90067-0PMID 3871245
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of normal and supersensitive dopamine receptors: Effects of ergot drugs and neuropeptides

  2005cited by this paper
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

  1984cited by this paper
• Pargyline prevents MPTP-induced parkinsonism in primates.

  1984cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

  1984cited by this paper
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983cited by this paper
• Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine.

  1980cited by this paper
• Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

  1979cited by this paper
• Depletion of brain noradrenaline and dopamine by 6‐hydroxydopamine

  1971cited by this paper

• A review on innovative approaches in quinoline/isoquinoline synthesis: Unveiling the Pummerer reaction strategy

  2024cites this paper
• Bacopa Protects against Neurotoxicity Induced by MPP+ and Methamphetamine

  2022cites this paper
• Optimisation and mechanistic insights of dyskinesia in rodent models of Parkinson’s disease

  2011cites this paper
• Induced Animal Models of Parkinson’s Disease

  2011cites this paper
• Early Toxicology Signal Generation in the Mouse

  2010cites this paper
• Interactions of HIV and methamphetamine: Cellular and molecular mechanisms of toxicity potentiation

  2007cites this paper
• Pesticides and Pesticide Mixtures Induce Neurotoxicity: Potentiation of Apoptosis and Oxidative Stress

  2006cites this paper
• Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man

  2005cites this paper
• Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinson's disease.

  2005cites this paper
• Caenorhabditis elegans MPP+ Model of Parkinson’s Disease for High-Throughput Drug Screenings

  2004cites this paper
• Conformational analysis and molecular properties of N-(substituted phenyl-carbonylamino)-4-(1-hydroxymethylphenyl)-1,2,3,6-tetrahydropyridines.

  2003cites this paper
• Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain.

  2002cites this paper
• Inhibitors of Na+/H+ and Na+/Ca2+ exchange potentiate methamphetamine‐induced dopamine neurotoxicity: possible role of ionic dysregulation in methamphetamine neurotoxicity

  2001cites this paper
• Suszeptibilitätsunterschiede im MPTP-Mausmodell für Morbus Parkinson: Untersuchung genetischer Einflußfaktoren anhand von Stammvergleichen

  2001cites this paper
• Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia.

  2001cites this paper
• The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies.

  2000cites this paper
• Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease.

  1998cites this paper
• L-DOPA exacerbates amphetamine-induced dopamine depletion.

  1998cites this paper
• R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells.

  1997cites this paper
• Increased expression of monoamine oxidase‐B results in enhanced neurite degeneration in methamphetamine‐treated PC12 cells

  1997cites this paper
• The neurotoxin MPTP increases calbindin-D28k levels in mouse midbrain dopaminergic neurons.

  1996cites this paper
• Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.

  1994cites this paper
• Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.

  1994cites this paper
• Comparison of brain dopamine depletion induced by low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in young and aged rats.

  1994cites this paper
• Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance.

  1994cites this paper
• Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging.

  1993cites this paper
• Differing Neurotoxic Potencies of Methamphetamine, Mazindol, and Cocaine in Mesencephalic Cultures

  1993cites this paper
• Stimulant-induced alterations in dopaminergic and serotonergic function in fetal raphe neurons.

  1993cites this paper
• Rodent Models of Parkinson’s Disease

  1992cites this paper
• Stereotaxic injection of GD1a ganglioside induces limited recovery of striatal dopaminergic system in MPTP‐treated aging mice

  1991cites this paper
• Acute Effects of 1‐Methyl‐4‐Phenyl‐1, 2, 3, 6‐Tetrahydropyridine in a Model of Rat Designated a Poor Metabolizer of Debrisoquine

  1991cites this paper
• Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine‐induced neuronal damage

  1991cites this paper
• The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat.

  1990cites this paper
• Limited recovery of striatal dopaminergic fibers by adrenal medullary grafts in MPTP-treated aging mice.

  1990cites this paper
• Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons.

  1990cites this paper
• Pargyline increases 6-hydroxydopamine levels in the neostriatum of methamphetamine-treated rats.

  1990cites this paper
• Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP.

  1990cites this paper
• Synthesis of some N‐[pyridyl(phenyl)carbonylamino]‐alkyl‐1,2,3,6‐tetrahydropyridines

  1990cites this paper
• Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.

  1990cites this paper
• Evalutation of the pharmacological similarities between phenlpopanolamine andamphetamine: Effects on schedule‐controlled behavior

  1990cites this paper
• Amine Oxidases and Their Impact on Neurobiology

  1990cites this paper
• 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced neurotoxicity in the rat: Characterization and age‐dependent effects

  1990cites this paper
• MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF).

  1990cites this paper
• MPTP is proconvulsant acutely but has no long-term effect in rodent models of seizure and epilepsy.

  1989cites this paper
• Methamphetamine-induced neuronal damage: a possible role for free radicals.

  1989cites this paper
• Age‐dependent effects of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): Correlation with monoamine oxidase‐B

  1989cites this paper
• Central depletion of dopamine in rats by 1-methyl-4-phenylpyridine.

  1989cites this paper
• 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'CH3-MPTP)-induced degeneration of mesostriatal dopaminergic neurons in the mouse: biochemical and neuroanatomical studies.

  1989cites this paper
• Selective decrease of immunoreactive tyrosine hydroxylase in nigrostriatum of adult male rats after N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment

  1988cites this paper
• The Effects of 1‐Methyl‐4‐phenylpyridinium Ion (MPP+) on the Efflux and Metabolism of Endogenous Dopamine in Rat Striatal Slices

  1988cites this paper
• Parkinsonian Syndrome Caused by 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Man and Animals

  1987cites this paper
• Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat.

  1987cites this paper
• Increased sensitivity of mice to tremorogenic agents following MPP+

  1987cites this paper
• Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice.

  1987cites this paper
• Pargyline and naltrexone fail to antagonize the gustatory avoidance response induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1986cites this paper
• Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase and tryptophan hydroxylase in rat.

  1986cites this paper
• MPTP: a pharmacological tool to study parkinsonism.

  1986cites this paper
• Mechanism of induction of Parkinson's disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chemical and electrochemical characterization of a geminal-dimethyl-blocked analog of a postulated toxic metabolite.

  1986cites this paper
• The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on presynaptic dopamine uptake sites in the mouse striatum.

  1986cites this paper
• The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1–methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine) and structurally related compounds

  1986cites this paper
• MPTP: current concepts and controversies.

  1986cites this paper
• Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults.

  1986cites this paper
• The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment.

  1986cites this paper
• Chronic organic manganese administration in the rat does not damage dopaminergic nigrostriatal neurons.

  1986cites this paper
• The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.

  1986cites this paper
• The Neurotoxin l-Methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease?

  1986cites this paper
• Amphetamine‐induced circling behaviour in MPTP‐lesioned mice

  1985cites this paper
• Age-dependent effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP).

  1985cites this paper
• Cocaine blocks the dopamine depletion induced by MPTP.

  1985cites this paper